$1.4
+0.06
(+4.87%)▲
Insights on Ikena Oncology Inc
Revenue is down for the last 6 quarters, 6.40M → 659.0K (in $), with an average decrease of 33.0% per quarter
Netprofit is down for the last 4 quarters, -12.92M → -19.48M (in $), with an average decrease of 15.4% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.2% return, outperforming this stock by 140.6%
In the last 3 years, Novo Nordisk A/s has given 234.2% return, outperforming this stock by 326.5%
5.36%
Downside
Day's Volatility :5.36%
Upside
0.0%
27.14%
Downside
52 Weeks Volatility :86.18%
Upside
81.03%
Period | Ikena Oncology Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -2.55% | 0.4% | 0.0% |
6 Months | -10.4% | 14.0% | 0.0% |
1 Year | -78.33% | 11.6% | -0.3% |
3 Years | -92.33% | 18.6% | -20.6% |
Market Capitalization | 64.2M |
Book Value | $3.22 |
Earnings Per Share (EPS) | -1.63 |
Wall Street Target Price | 8.33 |
Profit Margin | 0.0% |
Operating Margin TTM | -1963.76% |
Return On Assets TTM | -29.04% |
Return On Equity TTM | -48.28% |
Revenue TTM | 3.8M |
Revenue Per Share TTM | 0.09 |
Quarterly Revenue Growth YOY | -87.9% |
Gross Profit TTM | -48.7M |
EBITDA | -74.5M |
Diluted Eps TTM | -1.63 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.49 |
EPS Estimate Next Year | -1.22 |
EPS Estimate Current Quarter | -0.41 |
EPS Estimate Next Quarter | -0.39 |
What analysts predicted
Upside of 495.0%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 13.8M | - |
Net Income | -16.8M | - |
Net Profit Margin | -122.28% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 9.2M | ↓ 33.15% |
Net Income | -44.3M | ↑ 163.16% |
Net Profit Margin | -481.36% | ↓ 359.08% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 31.0M | ↑ 237.01% |
Net Income | -34.1M | ↓ 22.91% |
Net Profit Margin | -110.1% | ↑ 371.26% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 15.6M | ↓ 49.59% |
Net Income | -66.6M | ↑ 95.3% |
Net Profit Margin | -426.6% | ↓ 316.5% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 9.2M | ↓ 41.35% |
Net Income | -68.2M | ↑ 2.31% |
Net Profit Margin | -744.17% | ↓ 317.57% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 5.5M | ↓ 14.87% |
Net Income | -13.1M | ↓ 22.14% |
Net Profit Margin | -240.0% | ↑ 22.42% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 5.3M | ↓ 2.51% |
Net Income | -12.9M | ↓ 1.2% |
Net Profit Margin | -243.23% | ↓ 3.23% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.0M | ↓ 62.28% |
Net Income | -17.1M | ↑ 32.44% |
Net Profit Margin | -854.04% | ↓ 610.81% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.2M | ↓ 40.87% |
Net Income | -17.3M | ↑ 1.33% |
Net Profit Margin | -1.5K% | ↓ 609.5% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 659.0K | ↓ 44.39% |
Net Income | -19.5M | ↑ 12.37% |
Net Profit Margin | -3.0K% | ↓ 1493.82% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 86.0M | - |
Total Liabilities | 147.4M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 168.4M | ↑ 95.88% |
Total Liabilities | 269.5M | ↑ 82.76% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 247.9M | ↑ 47.19% |
Total Liabilities | 40.0M | ↓ 85.15% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 172.3M | ↓ 30.51% |
Total Liabilities | 25.3M | ↓ 36.78% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 192.1M | ↑ 11.51% |
Total Liabilities | 22.3M | ↓ 11.68% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 172.3M | ↓ 9.56% |
Total Liabilities | 25.3M | ↓ 20.17% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 152.4M | ↓ 11.53% |
Total Liabilities | 17.4M | ↓ 31.28% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 171.8M | ↑ 12.71% |
Total Liabilities | 15.1M | ↓ 13.32% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 215.3M | ↑ 25.37% |
Total Liabilities | 60.0M | ↑ 298.24% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 192.1M | ↓ 10.79% |
Total Liabilities | 22.3M | ↓ 62.77% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 172.8M | ↓ 10.05% |
Total Liabilities | 17.4M | ↓ 21.94% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -11.6M | - |
Investing Cash Flow | 11.0M | - |
Financing Cash Flow | 16.3M | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 47.9M | ↓ 512.88% |
Investing Cash Flow | -316.0K | ↓ 102.88% |
Financing Cash Flow | 16.3M | ↑ 0.0% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -37.8M | ↓ 178.92% |
Investing Cash Flow | 2.9M | ↓ 1024.68% |
Financing Cash Flow | 116.2M | ↑ 612.09% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -60.3M | ↑ 59.29% |
Investing Cash Flow | -1.8M | ↓ 160.23% |
Financing Cash Flow | 131.7M | ↑ 13.39% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -74.1M | ↑ 23.0% |
Investing Cash Flow | -99.3M | ↑ 5541.14% |
Financing Cash Flow | 1.1M | ↓ 99.17% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -17.7M | ↑ 2.53% |
Investing Cash Flow | 10.5M | ↓ 70.66% |
Financing Cash Flow | 1000.0 | ↓ 95.83% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -19.8M | ↑ 12.06% |
Investing Cash Flow | -10.8M | ↓ 202.92% |
Financing Cash Flow | 37.0M | ↑ 3700100.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -18.1M | ↓ 8.29% |
Investing Cash Flow | 22.7M | ↓ 309.88% |
Financing Cash Flow | 37.0M | ↑ 0.0% |
Sell
Neutral
Buy
Ikena Oncology Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Ikena Oncology Inc | 5.12% | -10.4% | -78.33% | -92.33% | -95.83% |
Moderna, Inc. | 24.35% | 68.6% | 3.16% | -19.55% | 450.13% |
Regeneron Pharmaceuticals, Inc. | 8.55% | 21.91% | 30.49% | 86.78% | 220.79% |
Novo Nordisk A/s | 6.83% | 35.3% | 59.23% | 234.23% | 468.67% |
Vertex Pharmaceuticals Incorporated | 11.29% | 24.82% | 28.22% | 102.21% | 159.28% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Ikena Oncology Inc | 5.29 | NA | NA | -1.49 | -0.48 | -0.29 | NA | 3.22 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 29.07 | 29.07 | 1.46 | 44.2 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.14 | 46.14 | 2.36 | 3.46 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 27.78 | 27.78 | 0.53 | 17.1 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Ikena Oncology Inc | Buy | $64.2M | -95.83% | 5.29 | 0.0% |
Moderna, Inc. | Buy | $49.2B | 450.13% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $107.6B | 220.79% | 29.07 | 29.45% |
Novo Nordisk A/s | Buy | $589.9B | 468.67% | 46.14 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $110.9B | 159.28% | 27.78 | 39.46% |
FMR Inc
Orbimed Advisors, LLC
Blue Owl Capital Holdings LP
BlackRock Inc
Vanguard Group Inc
Verition Fund Managegment, LLC
ikena oncology (formerly kyn therapeutics) is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients, by understanding what drives their disease. we are advancing multiple development and discovery programs: an ep4 receptor antagonist; an ahr antagonist; a kynurenine-degrading enzyme; a discovery-stage program targeting the hippo signaling pathway; and a discovery-stage program against an undisclosed target.. in addition to raising capital from top tier investors orbimed advisors and atlas venture, we have entered into a global strategic collaboration with celgene on the ahr antagonist and kynase programs. “at ikena, we begin with the end in mind. we focus on subgroups of patients based on their biomarker profiles who will most benefit from our immunotherapy and tumor cell-targeted drug candidates, ensuring that we can bring the right drug to the right patient battling cancer.” mark manfredi, chief executi
Organization | Ikena Oncology Inc |
Employees | 43 |
CEO | Dr. Mark Manfredi Ph.D. |
Industry | Services |
Sunlands Online Education Group
$1.40
+4.87%
Jianzhi Education Technology Group Company Ltd.
$1.40
+4.87%
Hireright Holdings Corp.
$1.40
+4.87%
Kura Sushi Usa Inc-class A
$1.40
+4.87%
Noodles & Co
$1.40
+4.87%
Regis Corp
$1.40
+4.87%
Gladstone Land Corporation
$1.40
+4.87%
Paysign, Inc.
$1.40
+4.87%
Jack In The Box Inc.
$1.40
+4.87%